

Clinical Updates From San Diego

Clinical Brief 2 – Addition of Daratumumab to VRd for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Results from the Phase 3 PERSEUS Trial

References

Tweet 3 References:

Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2023;doi:10.1056/NEJMoa2312054

Voorhees PM, Sborov DW, Laubach J, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. *Lancet Haematol*. 2023;10(10):e825-e837. doi:10.1016/S2352-3026(23)00217-X

Sonneveld P, Dimopoulos MA, Boccadoro M, et al. LBA-1 Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) versus Vrd alone in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplantation (ASCT): primary results of the Perseus trial. Presented at: ASH; December 9–12 2023; San Diego, CA. <https://ash.confex.com/ash/2023/webprogram/Paper191911.html>

Additional References:

Gay F, Roeloffzen W, Dimopoulos MA, et al. Results of the phase iii randomized Iskia Trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. *Blood*. 2023;142(Supplement 1):4-4. doi:10.1182/blood-2023-177546

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma (v3.2023). Updated December 8, 2022. Accessed February 28, 2023. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

Glossary

AE, adverse event

ASCT, autologous stem cell transplant

CI, confidence interval

CR, complete response

D, daratumumab

d, dexamethasone

DARA, daratumumab

HR, hazard ratio

MRD, minimal residual disease

NDMM, newly-diagnosed multiple myeloma

OR, odds ratio
OS, overall survival
P, phase
PFS, progression-free survival
PD, progressive disease
PS, performance status
R, lenalidomide
sCR, stringent complete response
SOC, standard of care
TE, transplant eligible
V, bortezomib
w/, with